Data are provided by many contributors through the the WHO Clinical data platform and are not necessarily representative. To become a contributor, please see the terms of use and register here.

Total cases

70

Total facilities

2

Total PLWH

7

Women

37.1%

Children below 5

12.9%

Total deaths

0

The map below is just a proof of concept. Can be adjusted once/if we have data at the regional level.

Geospatial distribution
Cases reported
Mirror plots
Chronic conditions
Variable Sample size Prevalence pct Frequency
HIV (Human Immunodeficiency Virus) 70 10.0% 7 / 70
Hypertension 70 5.7% 4 / 70
Current new STI (Sexually Transmitted Infection) diagnosis? 70 2.9% 2 / 70
Syphilis 2 100.0% 2 / 2
Chronic heart disease 70 0.0% 0 / 70
Chronic lung disease 70 0.0% 0 / 70
Chronic kidney disease 70 0.0% 0 / 70
Chronic liver disease 70 0.0% 0 / 70
Chronic neurologic condition 70 0.0% 0 / 70
Current alcohol use disorder 70 0.0% 0 / 70
Previous COVID-19 infection 70 0.0% 0 / 70
Diabetes 70 0.0% 0 / 70
Currently smokes tobacco 70 0.0% 0 / 70
Skin Conditions 70 0.0% 0 / 70
Tuberculosis (previous) 70 0.0% 0 / 70
Tuberculosis (active) 70 0.0% 0 / 70
Asplenia 70 0.0% 0 / 70
Cancer 70 0.0% 0 / 70
Immunosuppressive condition 70 0.0% 0 / 70
N. gonorrhoeae 2 0.0% 0 / 2
HSV 2 0.0% 0 / 2
Chlamydia trachomatis 2 0.0% 0 / 2
HPV 2 0.0% 0 / 2
AIDS - defining illness 6 0.0% 0 / 6

Source: WHO
Complications
Variable Sample size Prevalence pct Frequency
Cellulitis 58 19.0% 11 / 58
Bacteraemia 58 12.1% 7 / 58
Anaemia 58 3.4% 2 / 58
Bacterial Pneumonia 58 3.4% 2 / 58
Ocular Complications 58 3.4% 2 / 58
Abscess 58 3.4% 2 / 58
Sepsis 58 1.7% 1 / 58
Urinary Retention 58 1.7% 1 / 58
Shock 58 0.0% 0 / 58
Seizure 58 0.0% 0 / 58
Encephalitis / Meningitis 58 0.0% 0 / 58
Bleeding Disorder 58 0.0% 0 / 58
Stroke / Cerebrovascular Accident 58 0.0% 0 / 58
Guillain-Barré Syndrome 58 0.0% 0 / 58
Cardiac Arrest 58 0.0% 0 / 58
Cardiac Arrhythmia 58 0.0% 0 / 58
Cardiomyopathy 58 0.0% 0 / 58
Myocarditis / Pericarditis 58 0.0% 0 / 58
Viral Pneumonia / Pneumonitis 58 0.0% 0 / 58
Acute Respiratory Distress Syndrome (Ards) 58 0.0% 0 / 58
Acute Renal Injury / Acute Renal Failure 58 0.0% 0 / 58
Pancreatitis 58 0.0% 0 / 58
Liver Dysfunction 58 0.0% 0 / 58
Necrotizing Infection 58 0.0% 0 / 58
Proctitis 58 0.0% 0 / 58
Rectal Urgency 58 0.0% 0 / 58
Rectal Pain 58 0.0% 0 / 58

Source: WHO
Body map of lesions at admission
Prevalence of lesions at admission
Variable Sample size Prevalence pct Frequency
Upper limb 69 84.1% 58/69
Chest and abdomen 69 79.7% 55/69
Head and neck 69 78.3% 54/69
Lower limb 69 73.9% 51/69
Back 69 69.6% 48/69
Genitals 69 49.3% 34/69
Mouth 68 27.9% 19/68

Source: WHO
Type of lesions
Variable Sample size Prevalence pct Frequency
Papule 70 75.7% 53/70
Macule 70 57.1% 40/70
Umbilicated pustule 70 34.3% 24/70
Crusting of a mature lesion 70 34.3% 24/70
Small pustule 70 32.9% 23/70
Early vesicle 70 30.0% 21/70
Ulcerated lesion 70 27.1% 19/70
Partially removed scab 70 18.6% 13/70

Source: WHO
Reported symptoms
Symptoms at admission
Variable Sample size Prevalence pct Frequency
Fever 54 87.0% 47 / 54
Headache 70 65.7% 46 / 70
Muscle pain or aching 70 57.1% 40 / 70
Fatigue or malaise 70 57.1% 40 / 70
Pruritis/itching 54 63.0% 34 / 54
Sore throat 70 38.6% 27 / 70
Joint pain or aching 70 30.0% 21 / 70
Pain in mouth 70 27.1% 19 / 70
Swallowing problem 70 25.7% 18 / 70
Painful swallow 18 94.4% 17 / 18
Urinary symptoms 70 21.4% 15 / 70
Pain with urination 15 100.0% 15 / 15
Psychologic disturbance 70 14.3% 10 / 70
Dizziness 70 11.4% 8 / 70
Nausea 70 7.1% 5 / 70
Difficult swallow 18 27.8% 5 / 18
Ocular symptoms (pain, redness, visual loss) 70 4.3% 3 / 70
Decrease urine output 14 21.4% 3 / 14
Red eye(s) 3 100.0% 3 / 3
Vomiting 70 2.9% 2 / 70
Diarrhoea 70 2.9% 2 / 70
Any rectal symptom 70 2.9% 2 / 70
Chest pain 70 2.9% 2 / 70
Rectal pain 2 100.0% 2 / 2
Urethral discharge 15 6.7% 1 / 15
Eye pain 3 33.3% 1 / 3
Other 3 33.3% 1 / 3
Proctitis 70 0.0% 0 / 70
Rectal discharge 2 0.0% 0 / 2
Rectal urgency/tenesmus 2 0.0% 0 / 2
Visual disturbance 3 0.0% 0 / 3
...with blood 2 0.0% 0 / 2

Source: WHO
Symptoms at discharge
Variable Sample size Prevalence pct Frequency
Sore throat 58 1.7% 1 / 58
Muscle pain or aching 58 0.0% 0 / 58
Headache 58 0.0% 0 / 58
Ocular symptoms (pain, redness, visual loss) 58 0.0% 0 / 58
Fatigue or malaise 58 0.0% 0 / 58
Pain in mouth 58 0.0% 0 / 58
Nausea 58 0.0% 0 / 58
Vomiting 58 0.0% 0 / 58
Diarrhoea 58 0.0% 0 / 58
Any rectal symptom 58 0.0% 0 / 58
Swallowing problem 58 0.0% 0 / 58
Chest pain 58 0.0% 0 / 58
Joint pain or aching 58 0.0% 0 / 58
Proctitis 58 0.0% 0 / 58
Dizziness 58 0.0% 0 / 58
Psychologic disturbance 58 0.0% 0 / 58
Urinary symptoms 58 0.0% 0 / 58
Fever 46 0.0% 0 / 46
Pruritis/itching 45 0.0% 0 / 45

Source: WHO
Variable

Person with HIV
N = 7

Person without HIV
N = 60

Unknown
N = 3

 p-value 1
age, Median (Q1, Q3) 12.00 (8.00, 14.00) 8.00 (5.50, 9.00) 8.00 (8.00, 10.00) 0.068
    Missing/Unknown 1 0 0
Sex at birth, n (%)


0.14
    Male 4 (57%) 38 (63%) 1 (33%)
    Female 2 (29%) 22 (37%) 2 (67%)
    Intersex 0 (0%) 0 (0%) 0 (0%)
    Unknown 1 (14%) 0 (0%) 0 (0%)
Race, n (%)


0.6
    African/Black 6 (86%) 55 (92%) 3 (100%)
    Arab 0 (0%) 0 (0%) 0 (0%)
    Asian 0 (0%) 0 (0%) 0 (0%)
    Hispanic/Latino 0 (0%) 0 (0%) 0 (0%)
    Mixed Race 0 (0%) 0 (0%) 0 (0%)
    White 0 (0%) 0 (0%) 0 (0%)
    Unknown 1 (14%) 5 (8.3%) 0 (0%)
    Other 0 (0%) 0 (0%) 0 (0%)
health care worker, n (%)


0.3
    Yes 0 (0%) 0 (0%) 0 (0%)
    No 6 (86%) 59 (98%) 3 (100%)
    Unknown 1 (14%) 1 (1.7%) 0 (0%)
Laboratory worker, n (%)


0.5
    Yes 0 (0%) 0 (0%) 0 (0%)
    No 6 (86%) 57 (95%) 3 (100%)
    Unknown 1 (14%) 3 (5.0%) 0 (0%)
Sex worker, n (%)


0.013
    Yes 1 (14%) 2 (3.3%) 2 (67%)
    No 5 (71%) 54 (90%) 1 (33%)
    Unknown 1 (14%) 4 (6.7%) 0 (0%)
currently pregnant or was pregnant in the last 6 weeks?, n (%)


>0.9
    Yes 0 (0%) 1 (4.5%) 0 (0%)
    No 2 (100%) 21 (95%) 2 (100%)
    Unknown 0 (0%) 0 (0%) 0 (0%)
    Missing/Unknown 5 38 1
Breastfeeding, n (%)



    Yes 0 (NA%) 0 (NA%) 0 (NA%)
    No 0 (NA%) 0 (NA%) 0 (NA%)
    Unknown 0 (NA%) 0 (NA%) 0 (NA%)
    Missing/Unknown 7 60 3
1

Kruskal-Wallis rank sum test; Fisher’s exact test
Variable

Person with HIV
N = 7

Person without HIV
N = 60

Unknown
N = 3

 p-value 1
ever hospitalized, n (%)


>0.9
    Yes 4 (80%) 40 (78%) 1 (100%)
    No 1 (20%) 11 (22%) 0 (0%)
    Unknown 0 (0%) 0 (0%) 0 (0%)
    Missing/Unknown 2 9 2
Length of hospitalization, Median (Q1, Q3) 12 (9, 17) 6 (4, 11) 8 (8, 8) 0.2
    Missing/Unknown 3 20 2
Escalation of care, n (%)


0.11
    Yes 1 (25%) 0 (0%) 0 (0%)
    No 3 (75%) 40 (100%) 1 (100%)
    Unknown 0 (0%) 0 (0%) 0 (0%)
    Missing/Unknown 3 20 2
supplemental oxygen, n (%)


0.11
    Yes 1 (25%) 0 (0%) 0 (0%)
    No 3 (75%) 40 (100%) 1 (100%)
    Unknown 0 (0%) 0 (0%) 0 (0%)
    Missing/Unknown 3 20 2
receive nasogastric fluids, n (%)


>0.9
    Yes 0 (0%) 0 (0%) 0 (0%)
    No 5 (100%) 51 (100%) 2 (100%)
    Unknown 0 (0%) 0 (0%) 0 (0%)
    Missing/Unknown 2 9 1
receive IV fluids during course monkeypox infection, n (%)


0.067
    Yes 2 (40%) 2 (3.9%) 0 (0%)
    No 3 (60%) 49 (96%) 2 (100%)
    Unknown 0 (0%) 0 (0%) 0 (0%)
    Missing/Unknown 2 9 1
receive analgesia for pain management, n (%)


0.007
    Yes 5 (100%) 17 (33%) 1 (50%)
    No 0 (0%) 34 (67%) 1 (50%)
    Unknown 0 (0%) 0 (0%) 0 (0%)
    Missing/Unknown 2 9 1
receive antibiotics during course monkeypox infection, n (%)


0.2
    Yes 5 (100%) 47 (92%) 1 (50%)
    No 0 (0%) 4 (7.8%) 1 (50%)
    Unknown 0 (0%) 0 (0%) 0 (0%)
    Missing/Unknown 2 9 1
receive antifungals during course monkeypox infection, n (%)


>0.9
    Yes 0 (0%) 0 (0%) 0 (0%)
    No 5 (100%) 51 (100%) 2 (100%)
    Unknown 0 (0%) 0 (0%) 0 (0%)
    Missing/Unknown 2 9 1
experimental antiviral during course monkeypox infection, n (%)


>0.9
    Yes 0 (0%) 0 (0%) 0 (0%)
    No 5 (100%) 51 (100%) 1 (100%)
    Unknown 0 (0%) 0 (0%) 0 (0%)
    Missing/Unknown 2 9 2
1

Fisher’s exact test; Kruskal-Wallis rank sum test
Variable

Person with HIV
N = 7

Person without HIV
N = 60

Unknown
N = 3

 p-value 1
History of tetanus vaccination, n (%)


0.9
    Yes 0 (0%) 6 (10%) 0 (0%)
    No 2 (29%) 18 (30%) 0 (0%)
    Unknown 5 (71%) 36 (60%) 3 (100%)
History of smallpox vaccination before 1980, n (%)


0.2
    Yes 0 (0%) 0 (0%) 0 (0%)
    No 4 (57%) 49 (82%) 3 (100%)
    Unknown 3 (43%) 11 (18%) 0 (0%)
History of smallpox or monkeypox vaccination in past year, n (%)


0.5
    Yes 0 (0%) 0 (0%) 0 (0%)
    No 6 (86%) 56 (93%) 3 (100%)
    Unknown 1 (14%) 4 (6.7%) 0 (0%)
Number of vaccines received, Median (Q1, Q3) NA (NA, NA) NA (NA, NA) NA (NA, NA)
    Missing/Unknown 7 60 3
1

Fisher’s exact test
Variable

Person with HIV
N = 7

Person without HIV
N = 60

Unknown
N = 3

 p-value 1
New diagnosis of HIV, n (%)


0.018
    Yes 0 (0%) 0 (0%) 0 (0%)
    No 3 (100%) 51 (100%) 0 (0%)
    Unknown 0 (0%) 0 (0%) 1 (100%)
    Missing/Unknown 4 9 2
Current new STI (Sexually Transmitted Infection) diagnosis, n (%)



    Yes 0 (0%) 0 (NA%) 0 (NA%)
    No 2 (100%) 0 (NA%) 0 (NA%)
    Unknown 0 (0%) 0 (NA%) 0 (NA%)
    Missing/Unknown 5 60 3
Immunosuppressive condition, n (%)


0.043
    Yes 0 (0%) 0 (0%) 0 (0%)
    No 7 (100%) 60 (100%) 2 (67%)
    Unknown 0 (0%) 0 (0%) 1 (33%)
Most recent CD4, Median (Q1, Q3) 98 (98, 98) NA (NA, NA) NA (NA, NA)
    Missing/Unknown 1 60 3
Viral load, n (%)



    Detectable 0 (0%) 0 (NA%) 0 (NA%)
    Undetectable 3 (50%) 0 (NA%) 0 (NA%)
    Unknown 3 (50%) 0 (NA%) 0 (NA%)
    Missing/Unknown 1 60 3
AIDS - defining illness, n (%)



    Yes 0 (0%) 0 (NA%) 0 (NA%)
    No 6 (100%) 0 (NA%) 0 (NA%)
    Unknown 0 (0%) 0 (NA%) 0 (NA%)
    Missing/Unknown 1 60 3
1

Fisher’s exact test
Skin lesions by HIV status
Complications by HIV status
Exposure distribution
Variable Sample size Prevalence pct Frequency
Sexually active within ≤ 21 days prior to symptom onset? 70 45.7% 32/70
Number of heterosexual partners in the last three months 31 80.6% 25/31
Any known link to probable or confirmed case of monkeypox within ≤ 21 days prior to symptom onset? 70 10.0% 7/70
International travel within ≤ 21 days prior to symptom onset? 70 1.4% 1/70
Contact with possible animal source within ≤ 21 days prior to symptom onset? 70 0.0% 0/70
Did the patient receive experimental antiviral during course monkeypox infection? 57 0.0% 0/57

Source: WHO
Variable N = 70
Mpox clade known:, n (%)
    Yes 0 (0%)
    No 58 (100%)
    Unknown 0 (0%)
    Missing/Unknown 12
Mpox clade, n (%)
    Ia 0 (NA%)
    Ib 0 (NA%)
    IIa 0 (NA%)
    IIb 0 (NA%)
    Missing/Unknown 70
Monkeypox PCR, n (%)
    Yes 56 (97%)
    No 2 (3.4%)
    Unknown 0 (0%)
    Missing/Unknown 12
Monkeypox Result, n (%)
    Positive 24 (43%)
    Negative 29 (52%)
    Indeterminate 0 (0%)
    Unknown 3 (5.4%)
    Missing/Unknown 14
Monkeypox viral culture, n (%)
    Yes 0 (0%)
    No 58 (100%)
    Unknown 0 (0%)
    Missing/Unknown 12
Monkeypox viral culture Result, n (%)
    Positive 0 (NA%)
    Negative 0 (NA%)
    Indeterminate 0 (NA%)
    Unknown 0 (NA%)
    Missing/Unknown 70
Variable N = 70
Orthopoxvirus PCR, n (%)
    Yes 0 (0%)
    No 58 (100%)
    Unknown 0 (0%)
    Missing/Unknown 12
Orthopoxvirus Result, n (%)
    Positive 0 (NA%)
    Negative 0 (NA%)
    Indeterminate 0 (NA%)
    Unknown 0 (NA%)
    Missing/Unknown 70
Variable N = 70
Malaria result, n (%)
    Positive 0 (0%)
    Negative 1 (100%)
    Indeterminate 0 (0%)
    Unknown 0 (0%)
    Missing/Unknown 69
Syphilis result, n (%)
    Positive 1 (50%)
    Negative 1 (50%)
    Indeterminate 0 (0%)
    Unknown 0 (0%)
    Missing/Unknown 68
Variable

Baseline visit
N = 70
Hemoglobin, Median (Q1, Q3) 14.30 (11.10, 15.90)
WCC total, Median (Q1, Q3) 7.0 (6.1, 11.1)
Platelets, Median (Q1, Q3) 255 (156, 332)
PT, Median (Q1, Q3) NA (NA, NA)
APTT, Median (Q1, Q3) NA (NA, NA)
Total Bilirubin, Median (Q1, Q3) NA (NA, NA)
ALT, Median (Q1, Q3) NA (NA, NA)
AST, Median (Q1, Q3) NA (NA, NA)
Na+, Median (Q1, Q3) NA (NA, NA)
K+, Median (Q1, Q3) NA (NA, NA)
Urea/BUN, Median (Q1, Q3) NA (NA, NA)
Creatinine, Median (Q1, Q3) NA (NA, NA)
Glucose, Median (Q1, Q3) NA (NA, NA)
Lactate, Median (Q1, Q3) NA (NA, NA)
CRP, Median (Q1, Q3) NA (NA, NA)
Creatine kinase, Median (Q1, Q3) NA (NA, NA)
Variable

During infection management
N = 140
Hemoglobin, Median (Q1, Q3) 13.00 (11.40, 15.90)
WCC total, Median (Q1, Q3) 6.9 (5.1, 10.4)
Platelets, Median (Q1, Q3) 255 (159, 332)
PT, Median (Q1, Q3) NA (NA, NA)
APTT, Median (Q1, Q3) NA (NA, NA)
Total Bilirubin, Median (Q1, Q3) NA (NA, NA)
ALT, Median (Q1, Q3) NA (NA, NA)
AST, Median (Q1, Q3) NA (NA, NA)
Na+, Median (Q1, Q3) NA (NA, NA)
K+, Median (Q1, Q3) NA (NA, NA)
Urea/BUN, Median (Q1, Q3) NA (NA, NA)
Creatinine, Median (Q1, Q3) NA (NA, NA)
Glucose, Median (Q1, Q3) NA (NA, NA)
Lactate, Median (Q1, Q3) NA (NA, NA)
CRP, Median (Q1, Q3) NA (NA, NA)
Creatine kinase, Median (Q1, Q3) NA (NA, NA)
Variables Lab measures distribution
N Mean Median Min Max Distribution
Baseline visit
Hemoglobin 15.00 13.57 14.30 6.30 18.00
Platelets 15.00 279.93 255.00 93.00 731.00
WCC total 15.00 9.11 7.00 3.00 29.00
Outcomes